An Essential And Comprehensive Report On Biopharmaceuticals In The US And European Markets, By Research And Markets Research and Markets has announced the addition of the "Biopharmaceuticals in the US and European Markets" report to their offering.
Source: www.medicalnewstoday.comGene Associated With Pair-Bonding In Animals Has Similar Effects In Human Males Variation in the gene for one of the receptors for the hormone vasopressin appears to be associated with how human males bond with their partners, according to an international team of researchers. The researchers found that the "334" allele of a common AVPR1A variation, the human version of avpr1a studied in voles, seemed to have negative effects on men's relationship with their spouses.
Source: www.medicalnewstoday.comSARcode And Sunesis Announce Start Of Phase 1 Clinical Trial In Ocular Inflammatory Diseases SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases.
Source: www.medicalnewstoday.comCelator Pharmaceuticals Receives Orphan Drug Designation For Anticancer Agent CPX-351 Celator Pharmaceuticals announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for the treatment of Acute Myeloid Leukemia (AML). Celator is currently preparing to conduct two randomized Phase 2 studies with CPX-351. The first Phase 2 study, in newly diagnosed, elderly patients with AML, is expected to start enrolling patients before the end of 2008.
Source: www.medicalnewstoday.comAmgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].
Source: www.medicalnewstoday.comFDA Approves First Hepatitis B Viral Load Test The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to therapy.
Source: www.medicalnewstoday.comUSP's 2008 Annual Scientific Meeting To Convene Scientific Experts From Around The World The U.S. Pharmacopeial (USP) Convention's 2008 Annual Scientific Meeting (ASM) will be held in Kansas City, Mo., September 24 to 26. The meeting is an opportunity to interact with the USP experts responsible for establishing internationally recognized standards for
prescription and over-the-counter
medicines, food ingredients and dietary supplements. The focus will be on Quality of Manufactured
Medicines, Food Ingredients and Dietary Supplements.
Source: www.medicalnewstoday.com
# posted by Network @ 12:00 PM
